About Biopharma Credit (LON:BPCR)
BioPharma Credit Plc is a closed-ended investment company. The Company's investment objective is to generate long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry. The Company may acquire debt assets from a company operating in the life sciences industry or an entity other than a life sciences company, which directly or indirectly holds an interest in royalty rights to certain products, including any investment vehicle or special purpose vehicle. The Company's un-invested capital may be invested in cash instruments or bank deposits for cash management purposes. The Company may, from time to time, enter into such hedging or other derivative arrangements. The Company's investment manager is Pharmakon Advisors L.P.
Industry, Sector and Symbol
Industry Closed End Funds
Trailing P/E Ratio25.75
Forward P/E RatioN/A
Sales & Book Value
Price / SalesN/A
Price / CashN/A
Price / BookN/A
Trailing EPSGBX 0.04
Return on Equity5.84%
Return on Assets5.81%
Biopharma Credit (LON:BPCR) Frequently Asked Questions
What is Biopharma Credit's stock symbol?
Biopharma Credit trades on the London Stock Exchange (LON) under the ticker symbol "BPCR."
How often does Biopharma Credit pay dividends? What is the dividend yield for Biopharma Credit?
Biopharma Credit declared a dividend on Thursday, March 1st. Stockholders of record on Thursday, March 8th will be given a dividend of GBX 0.02 per share on Thursday, March 29th. This represents a dividend yield of 2.04%. The ex-dividend date is Thursday, March 8th. This is a boost from Biopharma Credit's previous dividend of $0.01. The official announcement can be seen at this link. View Biopharma Credit's Dividend History.
Who are some of Biopharma Credit's key competitors?
Some companies that are related to Biopharma Credit include AllianceBernstein Income Fund (ACG), Blackrock Taxable Municipal Bond Trust (BBN), John Laing Infrastructure Fund Ld (JLIF), Eaton Vance Tax Managed Buy Write Opport (ETV), BlackRock Enhanced Global Dividend Trust (BOE), Eaton Vance Floating-Rate Income Trust (EFT), Clearbridge Energy MLP Total Return Fund (CTR), MFS Charter Income Trust (MCR), Goldman Sachs MLP Inc Opp (GMZ), Carador Income Fund (CIFU), Oxford Lane Capital (OXLC), Center Coast Brookfield MLP&Enrg Inf Fnd (CEN), Kayne Anderson Energy Development (KED), BlackRock LT Municipal Advantage Trust (BTA), Voya Asia Pacific High (IAE), Malaysia Fund (MAY), Full Circle Capital (FULL) and GLI Finance (GLIF).
Who are Biopharma Credit's key executives?
Biopharma Credit's management team includes the folowing people:
- Jeremy W. Sillem, Chairman of the Board
- Colin Bond, Director (Age 56)
- Duncan W. A. Budge, Director (Age 61)
- Harry Abraham Hyman, Director
Has Biopharma Credit been receiving favorable news coverage?
Media headlines about BPCR stock have trended somewhat positive on Saturday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than twenty million blog and news sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Biopharma Credit earned a coverage optimism score of 0.08 on Accern's scale. They also gave headlines about the company an impact score of 45.98 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of Biopharma Credit?
Shares of BPCR and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
What is Biopharma Credit's stock price today?
One share of BPCR stock can currently be purchased for approximately GBX 1.03.
How big of a company is Biopharma Credit?
Biopharma Credit has a market capitalization of £937.11 million.
MarketBeat Community Rating for Biopharma Credit (BPCR)MarketBeat's community ratings are surveys of what our community members think about Biopharma Credit and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Biopharma Credit (LON:BPCR) Analyst Ratings History
No equities research coverage for this company has been tracked by MarketBeat
Earnings History for Biopharma Credit (LON:BPCR)
No earnings announcements for this company have been tracked by MarketBeat.com
Biopharma Credit (LON:BPCR) Earnings Estimates
No earnings estimates for this company have been tracked by MarketBeat.com
Biopharma Credit (LON:BPCR) Dividend History by Quarter
(Data available from 1/1/2013 forward)
|Announced||Period||Amount||Yield||Ex-Dividend Date||Record Date||Payable Date|
Biopharma Credit (LON BPCR) Insider Trading and Institutional Ownership History
Biopharma Credit (LON BPCR) Insider Trades by Quarter
(Data available from 1/1/2013 forward)
|Transaction Date||Insider Name||Title||Buy/Sell||Number of Shares||Average Share Price||Total Transaction||Shares Held After Transaction||Details|
|3/28/2017||Harry Abraham Hyman||Insider||Buy||2,000||GBX 82||£1,640|
Biopharma Credit (LON BPCR) News Headlines
Biopharma Credit (LON:BPCR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Biopharma Credit (LON BPCR) Stock Chart for Saturday, March, 24, 2018